<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917202</url>
  </required_header>
  <id_info>
    <org_study_id>S-237/2007</org_study_id>
    <nct_id>NCT00917202</nct_id>
  </id_info>
  <brief_title>Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8 Project of the SFB 544</brief_title>
  <official_title>Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <brief_summary>
    <textblock>
      Design: Single-centre, controlled study in adults with uncomplicated falciparum malaria in&#xD;
      the Nouna Health District, north-western Burkina Faso&#xD;
&#xD;
      Phase: Phase II&#xD;
&#xD;
      Objectives: The primary objective of this trial is to study the efficacy of different&#xD;
      methylene blue regimens given to adults with uncomplicated falciparum malaria in an African&#xD;
      area of high malaria transmission intensity.&#xD;
&#xD;
      Population: Male adults with uncomplicated malaria from Nouna town.&#xD;
&#xD;
      Sample size: N= 60 (n=20 for each group; three different dosing regimens of MB).&#xD;
&#xD;
      Treatment: The participants in the three different MB regimens will receive orally twice&#xD;
      daily 390 mg MB (total daily dose 780mg) over 7,5 or 3 days respectively. Treatment with the&#xD;
      five (three) day regimen will only start after all patients of the seven (five) days regimen&#xD;
      have been followed up until day 3.&#xD;
&#xD;
      Endpoints: The primary endpoint is the adequate clinical and parasitological response (ACPR)&#xD;
      rate on day 28. Secondary endpoints are the number of adverse events (AE) after drug intake&#xD;
      until day 28, clinical and parasitological failure rates on day 14 and 28, changes in&#xD;
      haemoglobin/haematocrit until day 28, and fever and parasite clearance time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Adequate clinical and parasitolgical response (ACPR) until D 28</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early treatment failure (ETF) rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late clinical failure (LCF) rate at D14 and D28</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late parasitological failure (LPF) rate at D14 and D28</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever clearance time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in haematocrit after 2,3,7,14 and 28 days compared to baseline</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of observed and self-reported non-serious adverse events over the 28 days observation period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events over the 28 days observation period</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MB whole blood concentrations (trough concentrations) on day 3,5 or 7 compared to trough concentrations after the first dose</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>MB3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MB7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylenblue</intervention_name>
    <arm_group_label>MB3</arm_group_label>
    <arm_group_label>MB5</arm_group_label>
    <arm_group_label>MB7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male adults (&gt;17 years;&lt;55 years)&#xD;
&#xD;
          -  Uncomplicated malaria caused by P. falciparum&#xD;
&#xD;
          -  Asexual parasites ≥ 1000/µl and ≤ 200 000/µl&#xD;
&#xD;
          -  Axillary temperatures ≥ 37.5°C or history of fever during 48 hours&#xD;
&#xD;
          -  Living in nouna Health District&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Complicated or severe malaria&#xD;
&#xD;
          -  Any apparent significant disease&#xD;
&#xD;
          -  Anaemia (haematocrit &lt; 21%)&#xD;
&#xD;
          -  Antimalarial treatment prior to inclusion (last three days)&#xD;
&#xD;
          -  Increased creatinine blood levels&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Nouna Health District</name>
      <address>
        <city>Nouna</city>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <last_update_submitted>June 9, 2009</last_update_submitted>
  <last_update_submitted_qc>June 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

